Zobrazeno 51 - 60
of 344
pro vyhledávání: '"Dennis Dong Hwan Kim"'
Autor:
Jonas Mattsson, Fotios V. Michelis, Rajat Kumar, Solaf Kanfar, Armin Gerbitz, Rehab M. Alblooshi, Wilson Lam, Bridgette Lord, Jeffrey H. Lipton, Auro Viswabandya, Zeyad Al-Shaibani, Arjun Law, Eshetu G. Atenafu, Ivan Pasic, Dennis Dong Hwan Kim
Publikováno v:
European Journal of Haematology. 106:32-39
Recent advances in allogeneic hematopoietic stem cell transplant (HSCT) have allowed us to offer HSCT to older, advanced disease patients with more co-morbidities. Cardiovascular toxicity post-transplant is a major concern due to the increased risk o
Autor:
Ga-Young Song, TaeHyung Kim, Seo-Yeon Ahn, Sung-Hoon Jung, Mihee Kim, Deok-Hwan Yang, Je-Jung Lee, Seung Hyun Choi, Mi Yeon Kim, Chul Won Jung, Jun-Ho Jang, Hee Je Kim, Joon Ho Moon, Sang Kyun Sohn, Jong-Ho Won, Seong-Kyu Park, Sung-Hyun Kim, Zhaolei Zhang, Jae-Sook Ahn, Hyeoung-Joon Kim, Dennis Dong Hwan Kim
Publikováno v:
Bone marrow transplantation. 57(12)
Secondary-type mutations (STMs), namely SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, and STAG2, are more frequently detected in secondary acute myeloid leukemia (AML) than in de novo AML. Whether de novo AML with STMs should be differently managed
Autor:
Tamir Biezuner, Yardena Brilon, Asaf Ben Arye, Barak Oron, Aditee Kadam, Adi Danin, Nili Furer, Mark D Minden, Dennis Dong Hwan Kim, Shiran Shapira, Nadir Arber, John Dick, Paaladinesh Thavendiranathan, Yoni Moskovitz, Nathali Kaushansky, Noa Chapal-Ilani, Liran I Shlush
Publikováno v:
NAR Genomics and Bioinformatics. 4
Deep targeted sequencing technologies are still not widely used in clinical practice due to the complexity of the methods and their cost. The Molecular Inversion Probes (MIP) technology is cost effective and scalable in the number of targets, however
Autor:
Courtney E Hershberger, Hassan Awada, Sunisa Kongkiatkamon, Hyeoung-Joon Kim, Claudia Haferlach, Jaroslaw P. Maciejewski, Mark D. Minden, Valeria Visconte, Dennis Dong Hwan Kim, Jae-Sook Ahn, Misam Zawit, Yihong Guan, Babal K. Jha, Carmelo Gurnari, Joop H. Jansen, Manja Meggendorfer, Torsten Haferlach, Vera Adema, Diego Coutinho, Ilana Zalcberg, Ying Ni, Simona Pagliuca
Publikováno v:
Blood Advances, 6, 100-107
Blood Advances, 6, 1, pp. 100-107
Blood Advances
Blood Advances, 6, 1, pp. 100-107
Blood Advances
Key Points 5-hydroxymethylcytosine and TET2 messenger RNA (mRNA) downregulation are common in myelodysplastic syndromes irrespective of TET2 mutations.TET3 mRNA expression levels are associated with distinct clinical outcomes in myelodysplastic syndr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4621e7720ab0d72f3aff865587c55ad
http://hdl.handle.net/2066/247767
http://hdl.handle.net/2066/247767
Autor:
Fotios V. Michelis, Maria Queralt Salas, Jeffrey H. Lipton, Dennis Dong Hwan Kim, Shiyi Chen, Arjun Datt Law, Wilson Lam, Armin Gerbitz, Zeyad Al-Shaibani, Jonas Mattsson, Ivan Pasic, Auro Viswabandya, Rajat Kumar
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:1511-1519
In this study, we compared the outcomes of patients with acute myelogenous leukemia (AML) in complete remission treated with myeloablative conditioning (MAC) and those treated with reduced-intensity conditioning (RIC) before allogeneic hematopoietic
Autor:
Auro Viswabandya, Maria Queralt Salas, M Remberger, Fotios V. Michelis, Rajat Kumar, Arjun Datt Law, Deepali Kumar, Wilson Lam, Jeffrey H. Lipton, Armin Gerbitz, Shruti Prem, Zeyad Al-Shaibani, Dennis Dong Hwan Kim, Jonas Mattsson
Publikováno v:
Leukemia & Lymphoma. 61:3198-3208
We explore risk factors and impacts of post-transplant EBV-Reactivation (EBV-R) and PTLD in 270 patients that underwent RIC alloHCT using ATG-PTCy and cyclosporine for GVHD prophylaxis. Twenty-five (12%) patients had probable (
Autor:
Maria Queralt Salas, Arjun Datt Law, Eshetu G. Atenafu, Jeffrey H. Lipton, Ivan Pasic, Wilson Lam, Ora Bascom, Zeyad Al-Shaibani, Dennis Dong Hwan Kim, Jonas Mattsson, Leeann Wilson, Fotios V. Michelis, Armin Gerbitz, Rajat Kumar, Auro Viswabandya, Shabbir M.H. Alibhai
Publikováno v:
Bone Marrow Transplantation. 56:60-69
A Frailty and Functionality evaluation for alloHCT was implemented using existing resources. We describe the implementation of this evaluation across all ages and at first consultation, and correlate results with posttransplant outcomes in 168 patien
Autor:
Arjun Datt Law, Dennis Dong Hwan Kim, Auro Viswabandya, Jeffrey H. Lipton, Jonas Mattsson, Wilson Lam, Fotios V. Michelis, Ivan Pasic, Rajat Kumar
Publikováno v:
Annals of Hematology. 99:1377-1387
Graft-versus-host disease (GVHD) represents a major contributor to morbidity and mortality in recipients of allogeneic hematopoietic cell transplants (HCT). Several strategies exist for GVHD prophylaxis and include post-transplant cyclophosphamide (P
Autor:
Ram V Nampoothiri, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Zeyad Al-Shaibani, Carol Chen, Dennis Dong Hwan Kim, Jonas Mattsson, Arjun Datt Law, Wilson Lam, Rajat Kumar, David Loach
Publikováno v:
European Journal of Haematology. 105:24-29
Introduction Therapy-related acute lymphoblastic leukemia (t-ALL) is an increasingly recognized subset of therapy-related acute leukemia. There are limited data on the role of allogeneic hematopoietic stem cell transplantation (HSCT) in t-ALL. Recent
Autor:
Fotios V. Michelis, Santhosh Thyagu, Alexander Js Bacopoulos, Lina Ho, David Loach, Celina Dara, Anjie Yang, Pamela Ng, Hans A. Messner, Jeffrey H. Lipton, Dennis Dong Hwan Kim, Uday Deotare, Auro Viswabandya
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:33-39
At our institution, tacrolimus is used as a second-line agent for the prevention and treatment of graft-versus-host-disease in the allogeneic hematopoietic stem cell transplantation (HSCT) unit after patients have experienced a serious or intolerable